Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KOSTAIVE-SOT Study in solid organ transplant recipients
jRCTs051260155Recruiting
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- Sep 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Open-label trial of ARCT-154 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Meiji Seika Pharma Co., Ltd. Primary endpoint: Seropositivity rate of anti-SARS-CoV-2 RBD IgG antibodies at Day 180 in the SOT group. Started Sep 2026; status: recruiting.
02
Drugs
ARCT-154
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCTs051260155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051260155.